ParkerVision, Inc. (PRKR) Is At $1.05 Formed Wedge; New Leaf Venture Partners Has Trimmed Sage Therapeutics (SAGE) Stake By $1.43 Million

January 15, 2018 - By Jerrie Dane

New Leaf Venture Partners Llc decreased Sage Therapeutics Inc (SAGE) stake by 33.89% reported in 2017Q3 SEC filing. New Leaf Venture Partners Llc sold 23,000 shares as Sage Therapeutics Inc (SAGE)’s stock rose 0.86%. The New Leaf Venture Partners Llc holds 44,872 shares with $2.80 million value, down from 67,872 last quarter. Sage Therapeutics Inc now has $7.22 billion valuation. The stock increased 0.72% or $1.26 during the last trading session, reaching $175.86. About 323,490 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since January 15, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

ParkerVision, Inc. (PRKR) formed wedge down with $0.98 target or 6.00% below today’s $1.05 share price. ParkerVision, Inc. (PRKR) has $20.58 million valuation. The stock increased 1.46% or $0.015 during the last trading session, reaching $1.045. About 336,534 shares traded or 90.08% up from the average. ParkerVision, Inc. (NASDAQ:PRKR) has declined 22.18% since January 15, 2017 and is downtrending. It has underperformed by 38.88% the S&P500.

Since December 14, 2017, it had 0 buys, and 2 insider sales for $17.36 million activity. 60,000 shares were sold by Robichaud Albert, worth $9.57M on Thursday, December 14. 44,000 shares were sold by Kanes Stephen, worth $7.80 million on Wednesday, January 10.

Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.23, from 0.98 in 2017Q2. It increased, as 33 investors sold SAGE shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. Eagle Asset Incorporated has invested 0.23% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Great West Life Assurance Can invested in 0% or 4,162 shares. Highland Capital Mgmt Ltd Partnership accumulated 20,000 shares. Deerfield Mngmt holds 0.19% or 68,000 shares in its portfolio. Bank Of Ny Mellon invested in 2.71 million shares or 0.05% of the stock. Rhenman Prtnrs Asset Mngmt Ab reported 50,000 shares. State Of Wisconsin Invest Board stated it has 33,334 shares or 0.01% of all its holdings. Savings Bank Of Nova Scotia invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Citigroup reported 39,026 shares. Fernwood Investment Mgmt Lc stated it has 8,400 shares or 0.33% of all its holdings. Price T Rowe Associates Inc Md, Maryland-based fund reported 4.67 million shares. Reilly Fincl Limited Liability stated it has 77 shares or 0% of all its holdings. Bb Biotech Ag holds 1.09 million shares or 1.88% of its portfolio. 32,500 are owned by Rock Springs Mngmt Limited Partnership. Farallon Capital Ltd Liability Com reported 243,500 shares stake.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 51 analyst reports since September 3, 2015 according to SRatingsIntel. On Tuesday, September 12 the stock rating was maintained by Cowen & Co with “Buy”. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, October 26. BMO Capital Markets has “Buy” rating and $80.0 target. As per Thursday, November 9, the company rating was maintained by BMO Capital Markets. RBC Capital Markets maintained the shares of SAGE in report on Thursday, November 2 with “Buy” rating. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Monday, October 16 by RBC Capital Markets. The firm earned “Buy” rating on Thursday, September 3 by Leerink Swann. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, October 19 by SunTrust. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Canaccord Genuity on Monday, November 13. The company was upgraded on Tuesday, February 14 by Chardan Capital Markets. As per Friday, November 10, the company rating was upgraded by Chardan Capital Markets.